By: Maribel Yoo On: May 15, 2018 In: Nexus Strategy, Portfolio Comments: 0

Personal Genome Diagnostics (PGDx) ( specializes in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomics and has developed novel technologies for non-invasive approaches to cancer.  The company is developing and commercializing a portfolio of tissue and liquid biopsy IVD cancer tests that will be clinically validated and regulated, enabling worldwide access to their technology. Headquartered in Baltimore, PGDx is one of the premier life sciences companies in the region.  It was established in 2010 by researchers from Johns Hopkins University who are among the world leaders in cancer genomics and in tissue-based and liquid biopsy technologies.

Deal Source

Dr. Bert Vogelstein

Board Representation

Felix Dawson